Fortrea Holdings (FTRE) Net Cash Flow (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Net Cash Flow came in at $21.9 million in Q2 2026, up 188.66% YoY from $7.6 million in Q2 2025, and up 187.6% on a QoQ basis from -$25.0 million in Q1 2026.
Fortrea Holdings (FTRE) Net Cash Flow (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Net Cash Flow data on file, last reported at $21.9 million in Q2 2026.
- Quarterly Net Cash Flow rose 188.66% year-over-year to $21.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $92.9 million (up 288.06% YoY) and the FY2025 annual result came in at $51.6 million, up 210.84% from the prior year.
- Net Cash Flow improved to $21.9 million in Q2 2026, from -$25.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $50.1 million in Q3 2025 to a low of -$25.0 million in Q1 2026.
- A 5-year average of $4.8 million and a median of $450000.0 in 2022 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 1047.06% in 2024, down 690.32% in 2024.
- Tracing FTRE's Net Cash Flow over 5 years: stood at -$800000.0 in 2022, then soared by 312.5% to $1.7 million in 2023, then surged by 1047.06% to $19.5 million in 2024, then surged by 135.38% to $45.9 million in 2025, then tumbled by 52.29% to $21.9 million in 2026.
- The last three Net Cash Flow figures came in at $21.9 million (Q2 2026), -$25.0 million (Q1 2026), and $45.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn | 21.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.90 Mn |
| Jun 30, 2026 | 21.90 Mn |
| Mar 31, 2026 | -25.00 Mn |
| Mar 31, 2026 | -25.00 Mn |
| Dec 31, 2025 | 45.90 Mn |
| Dec 31, 2025 | 45.90 Mn |
| Sep 30, 2025 | 50.10 Mn |
| Sep 30, 2025 | 50.10 Mn |
| Jun 30, 2025 | -24.70 Mn |
| Jun 30, 2025 | -24.70 Mn |
| Mar 31, 2025 | -19.70 Mn |
| Mar 31, 2025 | -19.70 Mn |
| Dec 31, 2024 | 19.50 Mn |
| Dec 31, 2024 | 19.50 Mn |
| Sep 30, 2024 | -24.50 Mn |
| Sep 30, 2024 | -24.50 Mn |
| Jun 30, 2024 | 35.10 Mn |
| Jun 30, 2024 | 35.10 Mn |
| Mar 31, 2024 | -13.50 Mn |
| Mar 31, 2024 | -13.50 Mn |